What 44 FY2026 NCI SBIR Awards Tell Cancer Diagnostic Device Founders About the Next Round
Executive summary
Across 44 NCI SBIR and STTR awards recorded in fiscal year 2026, totaling $34.9 million, roughly 71 percent of the dollars went to non-competing continuations of projects already underway. Only 16 awards, worth $10.0 million, were new starts. Of those new starts, nine were Phase II level R44s with a median award of $912,125, while only four were Phase I R43s, every one of which landed between $305,368 and $400,000. Diagnostics, imaging, instrumentation, and clinical software accounted for 15 of the 44 awards and 36 percent of the dollars, with a median award of $900,350, effectively identical to the therapeutics median of $888,779.
For a founder commercializing a cancer diagnostic device, the four decisions the data actually rewards are these. Enter at Phase II rather than Phase I when the feasibility data already exists. Frame the application so it routes to the imaging and instrumentation review panel rather than a therapeutics panel. Write aims around a named clinical decision the device changes, not around the technology itself. Design the Phase II milestone set so it doubles as the evidence package a third party investor will match against, because the NCI follow-on lane now requires that match.
What data is this analysis based on?
This analysis uses a NIH RePORTER export pulled on August 28, 2026, filtered to fiscal year 2026, administering institute NCI, and funding mechanism SBIR or STTR. The export returned 44 award records with award notice dates between May 14, 2026 and August 18, 2026.
Two caveats matter for interpretation. First, this is a late fiscal year slice rather than a complete twelve month picture, so the counts should be read as directional rather than as full year totals. Second, RePORTER reports fiscal year obligations, so a figure attached to a multi year Phase II reflects that year's funding rather than the total award value. Every dollar figure below is a fiscal year 2026 obligation.
How much of NCI's SBIR budget is actually available to new applicants?
Less than a third of it in any given cycle.
Of the 44 records, 28 are type 5 non-competing continuations representing $24,942,874. Only 16 are type 1 new awards representing $9,986,484, or 29 percent of the dollars in the slice. Support years run as high as year nine, and 15 of the continuations are in their third year or beyond.
The practical consequence is that the pool a first time applicant competes for is much smaller than headline institute budget numbers suggest. Most of what NCI spends on small business in a given year is servicing commitments it already made. Planning a company's capital strategy around the assumption that a large institute budget equals a large addressable pool is the most common structural mistake founders make with this program.
Does NCI fund more Phase I or Phase II applications?
New Phase II awards outnumbered new Phase I awards more than two to one in this slice.
Breaking the 16 new awards down by activity code:
Nine R44 awards, SBIR Phase II, with a median of $912,125 and a range from $306,872 to $1,216,515
Four R43 awards, SBIR Phase I, ranging from $305,368 to $400,000
Two R41 awards, STTR Phase I, at $399,855 and $400,000
One R42 award, STTR Phase II, at $348,352
Several of those new R44s are structurally interesting. Awards in the $306,000 to $404,000 range with an R44 activity code and a twelve month first budget period are Fast-Track applications sitting in their Phase I year. Awards near $900,000 to $1.2 million with a twenty four month budget period are Direct to Phase II or Fast-Track applications that went straight to Phase II scope. Intus Biosciences received $404,338 for a non-invasive bacterial-based early onset colorectal screen under the first pattern. Informed Medical Decisions received $1,216,515 to commercialize and integrate a hereditary cancer screening tool into electronic health records under the second.
For a diagnostic device company that has already generated analytical validation data outside of federal funding, Direct to Phase II is the mechanism the data points toward. It is accepted under the current parent SBIR announcement, it carries three to four times the budget of a Phase I, and in this slice it was the more common new award path.
How large are NCI SBIR Phase I awards in practice?
Every Phase I level award in this dataset fell between $305,368 and $404,338, clustering near $400,000.
This gap between ceiling and practice is worth understanding. Standard NIH budget guidelines for the current cycle sit near $323,090 for Phase I and $2,153,927 for Phase II, and those are guidelines rather than statutory caps. Individual institutes hold approval to exceed them, and NCI is among the institutes listing a Phase I limit as high as $700,000 for qualifying topics in the participating component table of the parent announcement.
Not one award in this slice used that headroom. The realistic planning number for an NCI SBIR Phase I is approximately $400,000 for twelve months. Founders who build a program plan around a waivered Phase I are budgeting against an outcome that did not occur once in 44 records. The place where NCI writes larger checks is Phase II, where fiscal year 2026 obligations in this slice reached $1,271,776 for a single year of one award.
Are diagnostics and devices funded as well as therapeutics at NCI?
On a per award dollar basis, yes.
Classifying the 44 awards by product type, 15 are diagnostics, imaging systems, instrumentation, or clinical software. Those 15 account for $12,649,547, which is 36 percent of the dollars in the slice, with a median award of $900,350. The remaining 29 awards, dominated by therapeutics, have a median of $888,779. There is no per award dollar penalty for being a device or diagnostic company at NCI.
Representative diagnostics and device awards in the slice include:
Surgivance, $1,271,776, rapid three dimensional point of care digital cancer pathology using confocal microscopy and downstream artificial intelligence
Rivanna Medical, $1,104,515, an artificial intelligence assisted ultrasound guidance platform to reduce traumatic lumbar puncture rates in pediatric oncology patients
AM Operating, $1,096,097, a visualization, labeling, and tracking engine for human anatomy
EpiCypher, $1,047,610, epigenomic analysis of cell-free nucleosomes
Leuko Labs, $991,877, PointCheck, a portable non-invasive neutropenia analyzer
LifeGene-BioMarks, $900,350, a precision DNA methylation test to reduce oral cancer disparities
Envisagenics, $889,653, a machine learning tool for identifying alternative splicing events
NE Scientific, $689,478, computer guided microwave liver ablation
RareCyte, $658,336, adaptive imaging for multiplexed spatial profiling of tumors and tissues
ONC.AI, $313,742, deep learning serial radiomics for cancer therapy response assessment
Where therapeutics do dominate is new award count. Among the 16 new starts, the therapeutics oriented review panels absorbed the majority of activity, which means the competitive density inside the diagnostics and device lane is thinner than the raw award split implies.
Which study section will review a cancer diagnostic device application?
Routing is the highest leverage decision in the entire application, and this dataset makes the routing map unusually legible.
Every imaging, instrumentation, and device guidance award in the slice was reviewed by the same special emphasis panel, ZRG1 ISB-Z (10) B. That panel handled Surgivance, Rivanna Medical, NE Scientific, RareCyte, and ONC.AI. It is the single most concentrated destination for hardware and imaging oriented cancer technology in the file.
Assay and biomarker diagnostics went somewhere else entirely. Intus Biosciences went to ZRG1 CDPT-F (11). Medara, developing a longitudinal multimodal risk prediction platform for personalized breast cancer screening, went to ZRG1 CDPT-A (13).
Diagnostics framed around care delivery, workflow integration, or health disparities went to the health services panels. LifeGene-BioMarks went to ZRG1 HSS-J (10) B, AM Operating to ZRG1 HSS-K (10) B, and Informed Medical Decisions to ZRG1 HSS-N (10).
Therapeutics clustered heavily in ZRG1 CDPT-E (12), which accounted for six awards, and the CTH and CDPT-V panels.
The same cancer diagnostic device, described three different ways, will be evaluated by three different reviewer pools with three different definitions of rigor. An instrumentation panel will interrogate optical performance, reproducibility, and manufacturability. A diagnostics panel will interrogate analytical and clinical validity, cohort design, and comparator assays. A health services panel will interrogate implementation, workflow, and outcome measurement. Choose the panel deliberately, write the specific aims to match its evaluative frame, and request the assignment explicitly in the cover letter rather than leaving referral to chance.
How concentrated is the NCI program officer landscape?
Eleven program officials of record cover all 44 awards.
Within the 15 diagnostics and device awards, one program official, Ming Zhao, is attached to five of them, covering ONC.AI, NE Scientific, Surgivance, LifeGene-BioMarks, and Envisagenics. Xing-Jian Lou is attached to three, and Linda Zane and Swamy Tripurani to two each.
This is a small and mappable group. Because every field used here is public in NIH RePORTER, a founder can identify the program officials who have actually managed portfolios resembling their technology, read the funded projects those officials oversee, and arrive at a pre-submission conversation with a specific, evidence grounded question rather than a general introduction. That conversation is where institute fit, mechanism choice, and budget headroom get resolved, and it is the single highest return hour of preparation available before submission.
What does the language of funded projects have in common?
Funded titles in this dataset describe a clinical delta rather than a technology.
Rivanna Medical did not sell an ultrasound platform. It sold reduced traumatic lumbar puncture rates in pediatric oncology patients. Leuko Labs did not sell a neutropenia analyzer. It sold a reduction in the incidence of febrile neutropenia in patients receiving chemotherapy. LifeGene-BioMarks did not sell a methylation assay. It sold reduced oral cancer disparities among African American patients in low resource settings. Informed Medical Decisions did not sell a screening tool. It sold commercialization and electronic health record integration of one.
Three recurring elements show up in the strongest diagnostics and device titles in the file. There is a named clinical decision or clinical event the device changes. There is a specified population, frequently pediatric, rare, underserved, or otherwise a documented NCI priority. And there is an outcome direction, usually a reduction in harm, delay, or disparity.
A title or aims page that leads with the sensor, the model architecture, or the platform is the exception in this dataset rather than the pattern.
Where does follow-on capital come from after Phase II?
The two longest running awards in the entire file are both follow-on bridge awards, and the mechanism that produced them has changed.
Leuko Labs appears at support year six with $991,877, and PRIVO Technologies appears at support year nine with $1,170,285 supporting a registration enabling Phase 3 clinical trial. Both sit under legacy NCI Phase IIB bridge announcements. That lane is the reason a small number of NCI small business projects reach registrational scale, and it is the part of the pathway most founders fail to plan for at the time they write their Phase I.
The current version is the NIH SBIR Phase IIB Strategic Breakthrough Award, PA-27-101. Two features drive strategy. First, applicants must secure third party matching funds equal to 100 percent of the NIH funds requested, from new private capital or new non-SBIR government funding. Second, NCI's implementation of the program is scoped more narrowly than the historical bridge, emphasizing late stage clinical development of therapeutic and medical device technologies addressing pediatric or rare cancer indications.
For a cancer diagnostic device, the implications are concrete. If the indication can be legitimately positioned in pediatric or rare cancer territory, the Strategic Breakthrough lane is available and the Phase II milestone plan should be designed to produce exactly the evidence a matching investor would underwrite. If it cannot, the Commercialization Readiness Pilot program, PAR-27-098, is the alternative, and it does not carry the third party match requirement. Either way, the decision belongs in the Phase I planning conversation, not in year two of Phase II.
How long does it take to get from submission to funding?
Roughly seven to nine months, and the award notice arrives with almost no lead time before the start date.
All 16 new awards in this slice carry notice dates between July 17 and August 18, 2026, with project start dates falling between zero and fifteen days after the notice. New Phase I budget periods almost uniformly end July 31, 2027. That is the signature of a January 5 submission moving through spring review, summer council, and an August 1 start, compressed against the end of the federal fiscal year.
Two operational implications follow. Companies must carry payroll and vendor costs through a seven to nine month gap with no certainty of an award, which is a working capital question rather than a grant writing question. And the notice to start interval is short enough that hiring, subcontracts, institutional review board submissions, and long lead equipment orders need to be staged before the notice arrives rather than after.
Which announcement should a cancer diagnostic device company apply to now?
Every opportunity number in this dataset is retired. The PA-24-245 through PA-24-248 omnibus series, which accounted for 23 of the 44 awards including 17 under PA-24-245 alone, has been replaced.
The current slate consists of PA-27-100, the parent SBIR announcement for R43 and R44 applications on a clinical trial optional basis, accepting Phase I, Phase II, Fast-Track, and Direct to Phase II submissions. PA-27-102 is the parallel parent STTR announcement for R41 and R42 applications where a nonprofit research institution partner carries a defined share of the work. PA-27-101 is the Phase IIB Strategic Breakthrough Award. PAR-27-098 is the Commercialization Readiness Pilot program.
Standard due dates are September 5, January 5, and April 5. In 2026, September 5 falls on a Saturday and the following Monday is the Labor Day federal holiday, which moves the operative receipt date to the next business day, Tuesday September 8, 2026. Applicants should confirm the date in the announcement itself before building a submission calendar around it.
For most companies reading this in late August, that September date is not a realistic target unless a complete package is already drafted, registrations are active, and letters of support are in hand. The achievable target is January 5, 2027, which by the timing pattern above implies an award start around August 2027. That is the schedule a founder should be capitalizing against.
Action checklist for a cancer diagnostic device company
Confirm whether existing feasibility and analytical validation data supports a Direct to Phase II submission rather than a Phase I, since that is where both the dollars and the new award volume sit
Budget a Phase I at approximately $400,000 for twelve months, and treat any larger figure as requiring explicit institute confirmation
Decide which review panel should evaluate the application, instrumentation, diagnostics, or health services, and write the specific aims to match that panel's evaluative frame
Request the study section assignment and the administering institute explicitly in the cover letter
Identify the program officials of record on funded projects resembling the technology, using public RePORTER fields, and schedule a pre-submission conversation with a specific question
Write the title and aims around a named clinical decision the device changes, a specified population, and a directional outcome
Determine now whether the indication can support a Phase IIB Strategic Breakthrough application, and if not, plan toward the Commercialization Readiness Pilot instead
Structure Phase II milestones so that completion produces the evidence package a third party investor would match
Verify SAM.gov, SBA company registry, eRA Commons, and Grants.gov registrations are active and current, since these routinely add weeks to a first submission
Plan working capital across a seven to nine month submission to funding gap, and stage hiring and subcontracts before the notice of award arrives
Frequently asked questions
How much can a cancer diagnostic device company receive from an NCI SBIR award? In this fiscal year 2026 dataset, Phase I level awards ranged from $305,368 to $404,338 and Phase II fiscal year obligations ranged from $271,378 to $1,271,776. Standard NIH budget guidelines for the current cycle sit near $323,090 for Phase I and $2,153,927 for Phase II, with institute specific waivers permitting higher amounts for qualifying topics.
Does NCI fund diagnostics and medical devices, or mainly therapeutics? Both. Diagnostics, imaging, instrumentation, and clinical software represented 15 of 44 awards and 36 percent of the dollars in this dataset, with a median award of $900,350 compared with $888,779 for the remaining, largely therapeutic, awards.
Which study section reviews cancer imaging and device SBIR applications? In this dataset, every imaging, instrumentation, and device guidance award was reviewed by special emphasis panel ZRG1 ISB-Z (10) B. Assay and biomarker diagnostics were reviewed by CDPT-A and CDPT-F panels, and diagnostics framed around workflow or disparities were reviewed by HSS panels.
Can a company skip Phase I and apply directly for Phase II? Yes. NIH accepts Direct to Phase II applications under the parent SBIR announcement for participating institutes when the company has already demonstrated the feasibility that a Phase I would otherwise establish. In this dataset, new Phase II level awards outnumbered new Phase I awards by more than two to one.
What is the next NIH SBIR deadline? Standard due dates are September 5, January 5, and April 5. Because September 5, 2026 falls on a Saturday ahead of the Labor Day holiday, the operative receipt date moves to the next business day, September 8, 2026. Applicants should confirm the date in the announcement.
How long does it take to receive funding after submitting? Roughly seven to nine months. In this dataset, new awards issued from a January submission carried notice dates in July and August with project starts within two weeks of the notice.
What comes after an NCI SBIR Phase II award? The Phase IIB Strategic Breakthrough Award, PA-27-101, provides follow-on funding but requires 100 percent third party matching funds, and NCI's implementation emphasizes pediatric and rare cancer indications for therapeutics and medical devices. Companies without a match, or needing technical assistance rather than a second Phase II, should evaluate the Commercialization Readiness Pilot program, PAR-27-098.
Does company location affect the odds of an NCI SBIR award? Not in a way this dataset supports. Awards went to companies in North Carolina, California, Massachusetts, and New York, and also to companies in Puerto Rico, Alabama, Wisconsin, Indiana, Delaware, South Carolina, Ohio, and Rhode Island.
About BW&CO
BW&CO is a non-dilutive federal funding advisory firm. We help deep-tech, biotech, medtech, and dual-use founders win SBIR, STTR, and related government funding without giving up equity. Our team has supported more than $350 million in funding secured across NIH, NSF, DoD, NASA, DOE, and ARPA-H.
Innovation Funding Simplified.
If you are developing a cancer diagnostic or medical device and evaluating the January 5, 2027 NIH cycle, we can assess mechanism fit, institute and study section routing, and budget strategy before you commit writing resources. Contact BW&CO to start that conversation.